Article Text

Download PDFPDF

1381 Discovery of ALG-093989, a highly potent and orally bioavailable small molecule PD-L1 inhibitor for the treatment of cancers
  1. Heleen Roose1,
  2. Kristina Rekstyte-Matiene1,
  3. Sarah Stevens2,
  4. Kusum Gupta2,
  5. Sandra Chang2,
  6. Cheng Liu2,
  7. Vladimir Serebryany2,
  8. Lillian Adame2,
  9. Kha Le2,
  10. Antitsa Stoycheva2,
  11. Lawrence M Blatt2,
  12. Leonid Beigelman2,
  13. Sushmita Chanda2,
  14. David B Smith2,
  15. Julian A Symons2,
  16. Andreas Jekle2 and
  17. Tongfei Wu1
  1. 1Aligos Belgium BV, Leuven, Vlaams-Brabant, Belgium
  2. 2Aligos Therapeutics, Inc., South San Francisco, CA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background PD-1/PD-L1 antibody-based therapies have demonstrated tremendous success in the treatment of a variety of cancers. However, these antibody drugs are associated with several disadvantages, such as weak tumor penetration, immune-related adverse events (irAEs) due to their long half-life and development of anti-drug antibodies. Here, we report the discovery of ALG-093989, a highly potent and orally bioavailable PD-L1 small molecule inhibitor, that may overcome the limitation of PD-1/PD-L1 antibodies.

Methods The biochemical interaction of PD-1/PD-L1 and PD-L1 dimerization was assessed by AlphaLISA®. Cellular activity was measured using a co-culture assay of PD-1 expressing Jurkat NFAT luciferase T cells with PD-L1 expressing CHO cells. Pharmacokinetic (PK) studies were performed in rat. In vivo PD-L1 target occupancy was assessed at 6 hours following a single oral dose in a humanized-PD-L1 MC38 subcutaneous mouse model.

Results ALG-093989 inhibits PD-1/PD-L1 interaction with an IC50 of 14 pM and induces PD-L1 dimerization with an EC50 of 13 nM. ALG-093989 has similar T-cell activation potency as durvalumab, and approximately 10-fold improved T-cell activation potency vs. INCB086550, a PD-L1 small molecule inhibitor that demonstrated clinical response in a phase I study. Oral bioavailability of ALG-093989 in rat following a single dose at 15 mg/kg dosing was 40%. In the in vivo humanized-PD-L1 MC38 mouse model, a single oral dose of ALG-093989 at 5 mg/kg demonstrated similar PD-L1 target occupancy to that of 150 mg/kg orally-administered INCB086550 and 5 mg/kg intravenously-administered durvalumab.

Conclusions We have discovered ALG-093989, a highly potent PD-L1 small molecule inhibitor, which shows similar T-cell activation potency as durvalumab, and ~ 10-fold improved T-cell activation potency vs. INCB086550. ALG-093989 has the same target occupancy in mice following oral dosing at a 30-fold lower dose than INCB03989. The properties of ALG-093989 warrant further evaluation as a potential candidate for drug development.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.